Drug safety evaluation of olanzapine pamoate

TY - JOUR

T1 - Drug safety evaluation of olanzapine pamoate

AU - Schöttle, Daniel

AU - Kuhnigk, Olaf

AU - Naber, Dieter

PY - 2013/11/1

Y1 - 2013/11/1

N2 - INTRODUCTION: Olanzapine pamoate is one of three second-generation antipsychotics available as depot medication. While non-adherence is a major problem in the treatment of schizophrenia, olanzapine pamoate can improve adherence, though its use is limited by its safety profile.AREAS COVERED: The review covers data on efficacy with a focus on tolerability and safety of olanzapine pamoate using the known databases including PubMed, Psychinfo and Embase using keywords. Relevant websites were also reviewed.EXPERT OPINION: Olanzapine is an efficacious antipsychotic that can be used in its oral and depot formula (olanzapine pamoate) for the treatment of patients with schizophrenia. It has demonstrated superiority over conventional and some other atypical antipsychotics, with both formulas having comparable low rates of motor side effects. The side effects on body weight and glucose homeostasis are also similar in both formulas and limit its use. The only clear difference regarding side effects is 'the risk that 0.07% of injections in preclinical trials have led to a post-injection delirium/sedation syndrome event which requires a risk management plan'. Especially in outpatients this could cause inconveniences that should be overcome by offering, for example, psychological therapies or psychoeducation to effectively use the time when patients have to remain in the healthcare facilities.

AB - INTRODUCTION: Olanzapine pamoate is one of three second-generation antipsychotics available as depot medication. While non-adherence is a major problem in the treatment of schizophrenia, olanzapine pamoate can improve adherence, though its use is limited by its safety profile.AREAS COVERED: The review covers data on efficacy with a focus on tolerability and safety of olanzapine pamoate using the known databases including PubMed, Psychinfo and Embase using keywords. Relevant websites were also reviewed.EXPERT OPINION: Olanzapine is an efficacious antipsychotic that can be used in its oral and depot formula (olanzapine pamoate) for the treatment of patients with schizophrenia. It has demonstrated superiority over conventional and some other atypical antipsychotics, with both formulas having comparable low rates of motor side effects. The side effects on body weight and glucose homeostasis are also similar in both formulas and limit its use. The only clear difference regarding side effects is 'the risk that 0.07% of injections in preclinical trials have led to a post-injection delirium/sedation syndrome event which requires a risk management plan'. Especially in outpatients this could cause inconveniences that should be overcome by offering, for example, psychological therapies or psychoeducation to effectively use the time when patients have to remain in the healthcare facilities.

KW - Antipsychotic Agents

KW - Benzodiazepines

KW - Delayed-Action Preparations

KW - Humans

KW - Medication Adherence

KW - Risk Management

KW - Schizophrenia

U2 - 10.1517/14740338.2013.832753

DO - 10.1517/14740338.2013.832753

M3 - SCORING: Journal article

C2 - 24024627

VL - 12

SP - 897

EP - 903

JO - EXPERT OPIN DRUG SAF

JF - EXPERT OPIN DRUG SAF

SN - 1474-0338

IS - 6

ER -